Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebivolol for Trastuzumab-Induced Cardiotoxicity in Breast Cancer
NCT07233499Phase 2Recruiting
- Sponsor
- Ain Shams University
- Start
- Jan 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nebivolol in Cardiotoxicity (2 arms), sponsored by Ain Shams University. Primary endpoint: Left Ventricular Ejection Fraction at 12 months. Started Jan 2025; status: recruiting.
02
Drugs
nebivolol
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT07233499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07233499.